ProMIS Neurosciences Inc. Insider Trading Activity
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Insider Trade Summary
Net Buyer: 539,100 shares
Net Buy
7 txns
Insider
Title 19 Promis
Role
10% Owner
Bought
539,100 shs ($0.00)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants to Purchase Common Shares | 539,100 | $0.00 | $0.00 |
| In-the-Money Exercise | Tranche A Common Share Purchase Warrants | 119,800 | $0.00 | $0.00 |
| In-the-Money Exercise | Tranche B Common Share Purchase Warrants | 119,800 | $0.00 | $0.00 |
| In-the-Money Exercise | Tranche C Common Share Purchase Warrants | 119,800 | $0.00 | $0.00 |
| In-the-Money Exercise | Common Shares, no par value | 119,800 | $0.00 | $0.00 |
| In-the-Money Exercise | Common Shares, no par value | 119,800 | $0.00 | $0.00 |
| In-the-Money Exercise | Common Shares, no par value | 119,800 | $0.00 | $0.00 |
Holdings After Transaction:
Tranche A Common Share Purchase Warrants — 345,316 warrants (Direct);
Tranche B Common Share Purchase Warrants — 345,316 warrants (Direct);
Tranche C Common Share Purchase Warrants — 345,316 warrants (Direct);
Warrants to Purchase Common Shares — 539,100 warrants (Direct);
Common Shares, no par value — 2,435,029 shares (Direct)
Holdings Before and After:
Tranche A Common Share Purchase Warrants, 465,116 to 345,316 warrants (Direct);
Tranche B Common Share Purchase Warrants, 465,116 to 345,316 warrants (Direct);
Tranche C Common Share Purchase Warrants, 465,116 to 345,316 warrants (Direct);
Warrants to Purchase Common Shares, 0 to 539,100 warrants (Direct);
Common Shares, no par value, 2,075,629 to 2,435,029 shares (Direct)
Footnotes (4)
- F1. On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
- F2. On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
- F3. On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
- F4. On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.
AI-generated analysis. How Rhea-AI works. Not financial advice.